Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma

Conditions: Hepatocellular Carcinoma Interventions: Drug: Recombinant Human Adenovirus Type 5; Drug: Lenvatinib; Drug: Tislelizumab Sponsors: First Affiliated Hospital Bengbu Medical College Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials